BeOne Medicines AG Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
BeOne Medicines AG (ONC) holds an ST Score of 63.3 out of 100 (B), with its strongest factor being Profitability (A+) and its weakest Financial Strength (D). Analysts rate ONC Buy across 14 ratings with a $401.56 average price target (+0.1% vs the current $350.84).
- Strongest
- ProfitabilityA+
- Weakest
- Financial StrengthD
All factor grades
- ProfitabilityA+
- GrowthA+
- MomentumA
- ForecastB
- ValuationD
- Financial StrengthD
- Piotroski6/9
Contact
ONC stock: frequently asked questions
What is ONC's ST Score?
BeOne Medicines AG (ONC) has an ST Score of 63.3 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ONC a buy, sell, or hold?
Wall Street's consensus rating on ONC is Buy based on 14 analyst ratings. Our own ST Score grades it B (63.3/100). This is data, not investment advice — always do your own research.
What is ONC's valuation grade?
BeOne Medicines AG (ONC) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ONC's growth grade?
BeOne Medicines AG (ONC) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ONC's profitability grade?
BeOne Medicines AG (ONC) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ONC's financial strength grade?
BeOne Medicines AG (ONC) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ONC?
The average analyst price target for BeOne Medicines AG (ONC) is $401.56 from 14 analysts, which is +0.1% versus the recent price of $350.84.
What is ONC's Piotroski score?
BeOne Medicines AG (ONC) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.